In contrast, 2 μM ZM treatment was sufficient to suppress hepatic steatosis and increase of HSC number at 27 hpt (Fig. 7B,C), suggesting that steatosis and HSC proliferation can be suppressed by VEGF inhibition without impairment of angiogenesis. This evidence concerns the gene VEGFA and fatty liver disease.